Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023)

Spyre Therapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $930000.0 for Q2 2023.

  • For Q2 2023, Current Deferred Revenue rose 210.0% year-over-year to $930000.0; the TTM value through Jun 2023 reached $930000.0, up 210.0%, while the annual FY2022 figure was $2.7 million, 14.29% up from the prior year.
  • Current Deferred Revenue reached $930000.0 in Q2 2023 per SYRE's latest filing, up from $302000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $21.5 million in Q1 2021 to a low of $300000.0 in Q2 2022.
  • Average Current Deferred Revenue over 3 years is $4.3 million, with a median of $2.5 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: crashed 94.55% in 2022, then skyrocketed 210.0% in 2023.
  • A 3-year view of Current Deferred Revenue shows it stood at $2.4 million in 2021, then grew by 14.29% to $2.7 million in 2022, then crashed by 65.5% to $930000.0 in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Current Deferred Revenue are $930000.0 (Q2 2023), $302000.0 (Q1 2023), and $2.7 million (Q4 2022).